{"id":117825,"date":"2021-11-02T12:34:59","date_gmt":"2021-11-02T11:34:59","guid":{"rendered":"https:\/\/eurecat.org\/?post_type=avada_portfolio&p=117825"},"modified":"2021-11-02T12:38:21","modified_gmt":"2021-11-02T11:38:21","slug":"emaps-cardio","status":"publish","type":"avada_portfolio","link":"https:\/\/eurecat.org\/en\/portfolio-items\/emaps-cardio\/","title":{"rendered":"EMAPS-CARDIO"},"content":{"rendered":"

\"EMAPS-CARDIO<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>

<\/h3><\/span>
<\/div><\/div><\/div>

Development of a new platform for growth and maturation of cardiac microtissues for adult-like organotypic models<\/strong>.<\/p>\n

The EMAPS-Cardio project<\/strong> proposes realistic heart models<\/strong> that can help to advance the understanding of several prevalent heart diseases, such as heart attacks and strokes, while striving to be sufficiently accurate to detect drug potency in both healthy and diseases tissues. To achieve this, biomimetic microenvironment, that provides all the needed stimuli, and biomechanical have been developed by combining electro-mechanoactive polymer-based scaffolds (EMAPS) with bioactive membranes.<\/p>\n

Currently, cardiovascular diseases (CVDs) account for 45% of deaths in Europe and are estimated to cost the EU economy \u20ac210 billion a year<\/strong>. However, only four drugs targeting cardiovascular diseases have been approved for use in the last decade. At this sense the EMAPS-Cardio has the main goal to achieve clinically relevant cardiac models for early-stage cardiovascular drug screening through:<\/p>\n